Cellectar Biosciences Культура компании

Mr. James V. Caruso, also known as Jim, has been the Chief Executive Officer and President of Cellectar Biosciences, Inc. since June 15, 2015. Mr. Caruso served as the Chief Commercial Officer and Executive Vice President of Allos Therapeutics Inc. from June 2006 to August 24, 2010. He served as Senior Vice President of Sales & Marketing at Bone Care International Inc. since November 2003 and served as Vice President, Sales from August 2002 to November 2003. He served as Head of Sales of Bone Care International Inc. since August 2002; Head of Marketing since August 2002 and Vice President- Sales from August 2002 to November 2003. He served as Executive Vice President, Chief Operating Officer and co-founder of HIP Innovation Technology, LLC. He was Vice President of Sales of the Neuroscience Business Unit at Novartis from June 2001 to August 2002. He served as Vice President of Sales at BASF Pharmaceuticals from June 2000 to June 2001 and from 1988 to June 2000. He held several positions at Bristol Myers Squibb including Director of Sales- West Coast and Senior Director of Serzone Marketing. Mr. Caruso has a wide range of expertise in both drugs and devices, including a strong background in oncology. He has more than 25 years of industry experience. He has been a Director at Cellectar Biosciences, Inc. since June 15, 2015. Mr. Caruso earned his Bachelor of Science degree in Finance from the University of Nevada.

Mr. Jarrod Longcor has been Chief Business Officer of Cellectar Biosciences, Inc., since September 18, 2017. Mr. Longcor served as Senior Vice President of Corporate Development and Operations at Cellectar Biosciences, Inc. since July 15, 2016 until September 18, 2017. Mr. Longcor has more than 20 years of pharmaceutical and biotech experience and during that time was either responsible for or participated in more than 40 collaborations. Mr. Longcor served as the Chief Business Officer of Avillion LLP since September 2014. He served as Vice President of Corporate Development at Melinta Therapeutics, Inc. (formerly, Rib-X Pharmaceuticals, Inc.) since July 2011. In this role, he was responsible for identifying and concluding several critical collaborations for the company, including a major discovery collaboration with Sanofi Aventis with a potential value of over $700 million. From July 2009 to June 2011, Mr. Longcor served as Senior Director of Business Development at Melinta Therapeutics, Inc. and served as its Director of Business Development from October 2007 to July 2009. Mr. Longcor joined Melinta Therapeutics, Inc. in 2007. His experience includes served as a Senior Director of Business Development at MaxCyte, Inc., where he was responsible for developing regional partnerships and Senior Director of Business Development of Advancis Pharmaceutical Corporation, where he was responsible primarily for the establishment and management of multiple partnerships. Mr. Longcor holds a B.S. from Dickinson College, a M.S. from Boston University School of Medicine and an MBA from Saint Joseph's University's Haub School of Business.

Dr. John E. Friend, II, M.D., has been Chief Medical Officer and Vice President of Cellectar Biosciences, Inc. since April 17, 2017. Dr. Friend has been the Chief Medical Officer and Vice President of Helsinn Therapeutics (U.S.), Inc. since April 17, 2017. Dr. Friend served as Senior Vice President of Research and Development at Helsinn Therapeutics (U.S.), Inc. Dr. Friend has 15 years of global drug development expertise and general management experience in oncology, inflammation, endocrine/metabolism and pain management to Cellectar. Prior to joining the company, Dr. Friend spent more than seven years at Helsinn Therapeutics leading its research and development division. Dr. Friend served as Senior Vice President of Medical and Scientific Affairs at Helsinn, building the non-clinical, clinical, medical and regulatory affairs teams to lead multiple global franchises from early product development to market commercialization. Prior to his time at Helsinn, Dr. Friend held executive responsibility for clinical research, medical affairs, pharmacovigilance and risk management at various pharmaceutical companies including Akros Pharma, Actavis, Alpharma, Hospira and Abbott. He completed post-graduate residency program in family medicine and subsequently served as Clinical Director and faculty attending physician at Cabarrus Family Medicine Residency Program in North Carolina. After obtaining an undergraduate degree in Chemistry from Southern Methodist University, Dr. Friend earned his medical degree from UMDNJ-Robert Wood Johnson Medical School (now Rutgers, RWJMS).